Core Insights - Phibro Animal Health Corporation (PAHC) is experiencing growth in its Animal Health business, driven by advancements in vaccine technologies and a rebound in Mineral Nutrition and Performance Product sectors [1][4][9] - The company's shares have significantly outperformed the industry and the S&P 500 over the past year, with a 107.9% increase compared to the industry's 20.9% and the S&P 500's 32.4% [2] - Phibro's market capitalization stands at $872 million, and it has consistently surpassed earnings estimates, achieving an average surprise of 25.47% over the last four quarters [2] Phibro's Key Tailwinds - The Animal Health business is benefiting from increased demand for efficient food production due to natural resource scarcity, with key products like Medicated Feed Additives (MFAs) and vaccines driving growth [4] - The company reported a 14% year-over-year sales growth in the Animal Health segment for the fiscal first quarter, with vaccine net sales increasing by 22% [6][8] - Phibro has expanded its vaccine manufacturing capacity, including a new facility in Brazil for autogenous vaccines targeting swine, poultry, and aquaculture [7] Recovery in Other Segments - The Mineral Nutrition business grew by 5% year-over-year, supported by increased demand for trace minerals, while Performance Products saw a 27% increase in sales [9] - Adjusted EBITDA for these segments increased by 64%, prompting the company to raise its fiscal 2025 sales guidance [9] Macroeconomic Concerns - Phibro's operations are facing challenges from macroeconomic factors such as economic sanctions, supply chain disruptions, and inflationary pressures, which could impact profitability [11] - The cost of goods sold increased by 8.1% compared to the previous year [12] Estimate Trends - The Zacks Consensus Estimate for fiscal 2025 earnings per share has increased by 2.5% to $1.61, with revenue estimates at $1.18 billion, reflecting a 15.6% rise from the previous year [13]

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a growth stock that can live up to its true potential can be a tough task.In addition to volatility, these stocks carry above-average risk by their very nature. Also, one could end up losing from a stock whose growth story is actually over or nearing its end.However, the Zacks Growth Style Score (part of the Zacks Style Scores sy ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help ...

Have you been paying attention to shares of Phibro Animal Health (PAHC) ? Shares have been on the move with the stock up 5.2% over the past month. The stock hit a new 52-week high of $25.61 in the previous session. Phibro Animal Health has gained 120.6% since the start of the year compared to the 4.7% move for the Zacks Medical sector and the 15% return for the Zacks Medical - Products industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as it hasn't missed ...

Have you evaluated the performance of Phibro Animal Health's (PAHC) international operations for the quarter ending September 2024? Given the extensive global presence of this maker of animal health products and nutritional supplements, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financi ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q1 2025 Earnings Conference Call November 7, 2024 9:00 AM ET Company Participants Glenn David - Chief Financial Officer Jack Bendheim - Chairman-Board of Directors, President & Chief Executive Officer Daniel Bendheim - Director & Executive Vice President-Corporate Strategy Larry Miller - Chief Operating Officer Conference Call Participants Ekaterina Knyazkova - JPMorgan Michael Ryskin - Bank of America Navann Ty - BNP Paribas Operator Hello, and thank you for s ...

Phibro Animal Health Corporation Webcast and Conference Call November 7, 2024 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2025 First Quarter Ended September 30, 2024 November 7, 2024 Webcast and Conference Call Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to any future debt and ...

Phibro Animal Health (PAHC) delivered adjusted earnings per share (EPS) of 35 cents in the first quarter of fiscal 2025 compared with 14 cents in the year-ago quarter. The bottom line beat the Zacks Consensus Estimate by 52.2%.Without adjustments, the GAAP EPS in the quarter was 17 cents compared to a loss of 20 cents in the prior-year period.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the announcement, PAHC shares rose nearly 8% in the after-hours trading yesterday.  PA ...

Phibro Animal Health (PAHC) reported $260.4 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 12.6%. EPS of $0.35 for the same period compares to $0.14 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $277.76 million, representing a surprise of -6.25%. The company delivered an EPS surprise of +52.17%, with the consensus EPS estimate being $0.23.While investors scrutinize revenue and earnings changes year-over-year and how they compa ...